|
20 Companies |
|
26 Products |
|
26 Products |
|
32 Mechanisms of Action |
|
0 Trials |
|
61 News |
|
| 12» |
- | Trial completion, Phase classification, Metastases: MRI Mapping in Planning Radiation Therapy to the Base of Skull and Brain in Patients With Nonmetastatic Head and Neck Cancer (clinicaltrials.gov) - Apr 23, 2019
P=N/A, N=3, Completed, Sponsor: Abramson Cancer Center of the University of Pennsylvania
Recruiting --> Completed | Phase classification: P1 --> PN/A
- | Trial termination: MRI in Finding Hypoxia in Patients Undergoing Chemo and Radiation for Head and Neck Cancer (clinicaltrials.gov) - Feb 18, 2019
P1, N=10, Terminated, Sponsor: University of Texas Southwestern Medical Center
Recruiting --> Completed | Phase classification: P1 --> PN/A Recruiting --> Terminated
- | cyclophosphamide / Generic mfg.
Phase classification, Trial termination, Metastases: Cyclophosphamide and Cryoablation in Treating Patients With Advanced or Metastatic Epithelial Cancer (clinicaltrials.gov) - Jan 18, 2019
P1, N=19, Terminated, Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Recruiting --> Terminated Phase classification: P=N/A --> P1 | Recruiting --> Terminated; The study was terminated per PI decision.
- | NN1213 / Novo Nordisk
Enrollment change, Trial initiation date, Trial termination, Metastases: Antineoplaston Therapy in Treating Patients With Advanced Head and Neck Cancer (clinicaltrials.gov) - Sep 28, 2017
P2, N=7, Terminated, Sponsor: Burzynski Research Institute
Phase classification: P=N/A --> P1 | Recruiting --> Terminated; The study was terminated per PI decision. N=40 --> 7 | Initiation date: Aug 1998 --> May 1996 | Active, not recruiting --> Terminated; slow accrual
- | doxepin / Generic mfg.
Trial completion: Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy (clinicaltrials.gov) - Aug 9, 2017
P3, N=155, Completed, Sponsor: Alliance for Clinical Trials in Oncology
N=40 --> 7 | Initiation date: Aug 1998 --> May 1996 | Active, not recruiting --> Terminated; slow accrual Active, not recruiting --> Completed
- | docetaxel / Generic mfg.
Trial completion, Trial primary completion date: Studying DNA in Tissue Samples From Caucasian and African-American Cancer Patients Who Received Docetaxel on Clinical Trial CLB-9871 (clinicaltrials.gov) - Jul 13, 2017
P=N/A, N=69, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jan 2013
- Trial completion: High-dose ICE With Amifostine (clinicaltrials.gov) - Jan 23, 2017
P2, N=24, Completed, Sponsor: Dana-Farber Cancer Institute
Active, not recruiting --> Completed | Trial primary completion date: Jan 2100 --> Jan 2013 Active, not recruiting --> Completed
- | fluconazole oral / Generic mfg.
Trial completion: Fluconazole in Preventing Mucositis in Patients Undergoing Radiation Therapy for Head and Neck Cancer (clinicaltrials.gov) - Dec 14, 2016
P2/3, N=0, Completed, Sponsor: University of Miami
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion: Zinc Sulfate in Preventing Loss of Sense of Taste in Patients Undergoing Radiation Therapy for Head and Neck Cancer (clinicaltrials.gov) - Jul 12, 2016
P3, N=173, Completed, Sponsor: Alliance for Clinical Trials in Oncology
Not yet recruiting --> Completed No longer recruiting --> Completed
- | docetaxel / Generic mfg.
Trial completion: Docetaxel in Treating Patients With Solid Tumors (clinicaltrials.gov) - Jul 12, 2016
P2, N=109, Completed, Sponsor: Alliance for Clinical Trials in Oncology
No longer recruiting --> Completed Active, not recruiting --> Completed
- Trial completion, HEOR: Head & Neck Cancer Survivorship: Physical and Functional Status (clinicaltrials.gov) - Dec 12, 2015
P1, N=23, Completed, Sponsor: Vanderbilt University
Active, not recruiting --> Completed Active, not recruiting --> Completed
- pemetrexed / Generic mfg., docetaxel / Generic mfg.
Trial completion, Enrollment change, Trial primary completion date, Combination therapy, Metastases: Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Dec 5, 2015
P1, N=33, Completed, Sponsor: University of Arizona
Active, not recruiting --> Completed Active, not recruiting --> Completed | N=54 --> 33 | Trial primary completion date: Apr 2014 --> Jul 2014
- | Trial completion, Adverse events, Metastases: Side Effects of High-Dose Intensity-Modulated Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer (clinicaltrials.gov) - Oct 16, 2015
P=N/A, N=20, Completed, Sponsor: University of Wisconsin, Madison
Active, not recruiting --> Completed | N=54 --> 33 | Trial primary completion date: Apr 2014 --> Jul 2014 Active, not recruiting --> Completed
- NN1213 / Novo Nordisk
Trial completion: Physician-Initiated Stop-Smoking Program for Patients Receiving Treatment for Early-Stage Cancer (clinicaltrials.gov) - Oct 7, 2015
P=N/A, N=434, Completed, Sponsor: Eastern Cooperative Oncology Group
Active, not recruiting --> Completed Active, not recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Trial completion, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Sep 30, 2015
P1, N=43, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- docetaxel / Generic mfg.
Trial initiation date, Trial primary completion date: Studying DNA in Tissue Samples From Caucasian and African-American Cancer Patients Who Received Docetaxel on Clinical Trial CLB-9871 (clinicaltrials.gov) - Jul 20, 2015
P=N/A, N=69, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Active, not recruiting --> Completed Initiation date: Feb 2009 --> Oct 2008 | Trial primary completion date: May 2010 --> Jan 2100
- | NN1213 / Novo Nordisk
Trial completion, Metastases: Vaccine Therapy in Treating Patients With Advanced or Recurrent Cancer (clinicaltrials.gov) - Apr 27, 2015
P1, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Initiation date: Feb 2009 --> Oct 2008 | Trial primary completion date: May 2010 --> Jan 2100 No longer recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Phase classification, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Sep 28, 2014
P1, N=43, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
No longer recruiting --> Completed Phase classification: P1/2 --> P1
- erlotinib / Generic mfg.
Trial termination: Erlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the Lung (clinicaltrials.gov) - Sep 15, 2014
P1, N=60, Terminated, Sponsor: National Cancer Institute (NCI)
Phase classification: P1/2 --> P1 Active, not recruiting --> Terminated
- Trial withdrawal: Insomnia in Patients Undergoing Chemotherapy and Radiation Therapy for Head and Neck Cancer (clinicaltrials.gov) - Jun 18, 2014
P=N/A, N=0, Withdrawn, Sponsor: Vanderbilt University
Active, not recruiting --> Terminated Terminated --> Withdrawn
- Enrollment change, Trial withdrawal: Insomnia in Patients Undergoing Chemotherapy and Radiation Therapy for Head and Neck Cancer (clinicaltrials.gov) - Jun 18, 2014
P=N/A, N=0, Withdrawn, Sponsor: Vanderbilt University
Terminated --> Withdrawn N=50 --> 0 | Terminated --> Withdrawn
- Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial primary completion date, Combination therapy, Metastases: Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 12, 2014
P1/2, N=66, Completed, Sponsor: National Cancer Institute (NCI)
N=50 --> 0 | Terminated --> Withdrawn Trial primary completion date: Jul 2008 --> Oct 2007
- | Avastin (bevacizumab) / Roche, Erbitux (cetuximab) / Eli Lilly
Trial completion, Combination therapy, Metastases: Erlotinib and Cetuximab With or Without Bevacizumab in Treating Patients With Metastatic or Unresectable Kidney, Colorectal, Head and Neck, Pancreatic, or Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jun 9, 2014
P1/2, N=66, Completed, Sponsor: National Cancer Institute (NCI)
Trial primary completion date: Jul 2008 --> Oct 2007 Recruiting --> Completed
- | doxepin / Generic mfg.
Enrollment closed: Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy (clinicaltrials.gov) - May 13, 2014
P3, N=162, Active, not recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Recruiting --> Completed Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Enrollment change, Adverse events: Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer (clinicaltrials.gov) - Apr 20, 2014
P2, N=11, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting N=16 --> 11
- | NN1213 / Novo Nordisk
Trial completion, Surgery: Acupuncture or Standard Therapy in Treating Pain and Dysfunction in Patients Who Have Undergone Neck Surgery for Head and Neck Cancer (clinicaltrials.gov) - Feb 22, 2014
P3, N=73, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
N=16 --> 11 Active, not recruiting --> Completed
- | NN1213 / Novo Nordisk
Trial completion, Metastases: Alvespimycin Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors (clinicaltrials.gov) - Feb 22, 2014
P1, N=30, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | thalidomide / Generic mfg., docetaxel / Generic mfg.
Trial completion, Metastases: Thalidomide and Docetaxel in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Feb 22, 2014
P1, N=26, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Zolinza (vorinostat) / Merck (MSD)
Trial completion, Metastases: Suberoylanilide Hydroxamic Acid in Treating Patients With Advanced Cancer (clinicaltrials.gov) - Feb 22, 2014
P1, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | erlotinib / Generic mfg.
Trial completion: Erlotinib in Treating Patients With Solid Tumors and Liver or Kidney Dysfunction (clinicaltrials.gov) - Feb 22, 2014
P1, N=75, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Suspended --> Completed
- | Avastin (bevacizumab) / Roche
Trial completion, Metastases: Bevacizumab, Fluorouracil, and Hydroxyurea Plus Radiation Therapy in Treating Patients With Advanced Head and Neck Cancer (clinicaltrials.gov) - Feb 22, 2014
P1, N=39, Completed, Sponsor: National Cancer Institute (NCI)
Suspended --> Completed Active, not recruiting --> Completed
- | Neupogen (filgrastim) / Kyowa Kirin, Amgen
Trial completion, Combination therapy: Paclitaxel and Cisplatin Plus Radiation Therapy Followed by Filgrastim in Treating Patients With Recurrent Head and Neck Cancer or Lung Cancer (clinicaltrials.gov) - Feb 19, 2014
P2, N=29, Completed, Sponsor: Fox Chase Cancer Center
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Jingzhuda (entinostat) / EOC Pharma, EddingPharm
Trial completion, Epigenetic controller, Metastases: MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma (clinicaltrials.gov) - Feb 19, 2014
P1, N=75, Completed, Sponsor: National Institutes of Health Clinical Center (CC)
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Leukine (sargramostim) / Partner Therap
Trial completion, Metastases: Vaccine Therapy Plus Biological Therapy in Treating Adults With Metastatic Solid Tumors (clinicaltrials.gov) - Feb 19, 2014
P2, N=0, Completed, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed No longer recruiting --> Completed
- NN1213 / Novo Nordisk
Trial completion: Cevimeline in Treating Patients With Dry Mouth Caused by Radiation Therapy for Head and Neck Cancer (clinicaltrials.gov) - Feb 19, 2014
P3, N=0, Completed, Sponsor: Daiichi Sankyo Inc.
No longer recruiting --> Completed Not yet recruiting --> Completed
- | cisplatin / Generic mfg., capecitabine / Generic mfg.
Trial completion, Metastases: Capecitabine Combined With Cisplatin in Treating Patients With Locally Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: New York University School of Medicine
Not yet recruiting --> Completed Active, not recruiting --> Completed
- | semaxanib (SU5416) / Pfizer
Trial completion, Metastases: SU5416 and Paclitaxel in Treating Patients With Recurrent, Locally Advanced or Metastatic Cancer of the Head and Neck (clinicaltrials.gov) - Feb 19, 2014
P1, N=12, Completed, Sponsor: Case Comprehensive Cancer Center
Active, not recruiting --> Completed Not yet recruiting --> Completed
- | tanespimycin (BMS-722782) / BMS, NN1213 / Novo Nordisk
Trial completion, Metastases: Chemotherapy in Treating Patients With Refractory Advanced Solid Tumors or Hematologic Cancer (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Not yet recruiting --> Completed Not yet recruiting --> Completed
- | Genasense (oblimersen) / Genta
Trial completion, Metastases: Chemotherapy in Treating Patients With Solid Tumors (clinicaltrials.gov) - Feb 19, 2014
P1/2, N=57, Completed, Sponsor: Memorial Sloan-Kettering Cancer Center
Not yet recruiting --> Completed Active, not recruiting --> Completed
- | docetaxel / Generic mfg.
Trial completion, Metastases: Docetaxel in Treating Patients With Solid Tumors and Abnormal Liver Function (clinicaltrials.gov) - Feb 19, 2014
P1, N=0, Completed, Sponsor: City of Hope Medical Center
Active, not recruiting --> Completed Not yet recruiting --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment change, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Feb 9, 2014
P1/2, N=43, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Not yet recruiting --> Completed N=55 --> 43
- pemetrexed / Generic mfg., docetaxel / Generic mfg.
Enrollment closed, Combination therapy, Metastases: Pemetrexed Disodium and Docetaxel in Treating Patients With Advanced Solid Tumors (clinicaltrials.gov) - Feb 5, 2014
P1, N=54, Active, not recruiting, Sponsor: University of Arizona
N=55 --> 43 Recruiting --> Active, not recruiting
- 7-Hydroxystaurosporine (UCN-01) / National Cancer Institute
Trial completion, Combination therapy, Metastases: 7-Hydroxystaurosporine and Irinotecan Hydrochloride in Treating Patients With Metastatic or Unresectable Solid Tumors or Triple Negative Breast Cancer (Currently Accruing Only Triple-negative Breast Cancer Patients Since 6/8/2007) (clinicaltrials.gov) - Jun 30, 2013
P1, N=41, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Active, not recruiting --> Completed
- erlotinib / Generic mfg.
Enrollment closed: Erlotinib Hydrochloride in Preventing Cancer in Patients With Precancerous Lesions of the Lung (clinicaltrials.gov) - Apr 30, 2013
P1, N=60, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- Avastin (bevacizumab) / Roche
Trial initiation date, Adverse events: Bevacizumab in Reducing CNS Side Effects in Patients Who Have Undergone Radiation Therapy to the Brain for Primary Brain Tumor, Meningioma, or Head and Neck Cancer (clinicaltrials.gov) - Apr 8, 2013
P2, N=16, Completed, Sponsor: National Cancer Institute (NCI)
Recruiting --> Active, not recruiting Initiation date: Feb 2007 --> Jun 2007
- Erbitux (cetuximab) / Eli Lilly
Trial completion: Immunoreactivity to Cetuximab in Cancer Patients (clinicaltrials.gov) - Mar 28, 2013
P=N/A, N=538, Completed, Sponsor: Vanderbilt-Ingram Cancer Center
Initiation date: Feb 2007 --> Jun 2007 Active, not recruiting --> Completed
- |||||| doxepin / Generic mfg.
Enrollment open: Doxepin Hydrochloride in Treating Oral Mucositis Pain in Patients With Head and Neck Cancer Undergoing Radiation Therapy With or Without Chemotherapy (clinicaltrials.gov) - Jan 15, 2013
P3, N=198, Recruiting, Sponsor: North Central Cancer Treatment Group
Active, not recruiting --> Completed Completed --> Recruiting
- gefitinib / Generic mfg.
Trial completion, Metastases: Gefitinib in Treating Patients With Metastatic or Unresectable Head and Neck Cancer or Non-Small Cell Lung Cancer (clinicaltrials.gov) - Jan 10, 2013
P=N/A, N=40, Completed, Sponsor: National Cancer Institute (NCI)
Completed --> Recruiting Terminated --> Completed
- Erbitux (cetuximab) / Eli Lilly, EMD Serono
Enrollment closed, Metastases: Erlotinib Hydrochloride and Cetuximab in Treating Patients With Advanced Gastrointestinal Cancer, Head and Neck Cancer, Non-Small Cell Lung Cancer, or Colorectal Cancer (clinicaltrials.gov) - Jan 7, 2013
P1/2, N=43, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Terminated --> Completed Recruiting --> Active, not recruiting
- Enrollment change, HEOR: AMWELL-SL: Using Traditional Acupuncture in the Management of Cancer Treatment Related Lymphoedema (clinicaltrials.gov) - Dec 6, 2012
P=N/A, N=56, Completed, Sponsor: East and North Hertfordshire NHS Trust
Recruiting --> Active, not recruiting N=40 --> 56